Managing Editor, In Vivo
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.
Founding CEO of the UK’s Cell and Gene Therapy Catapult, Keith Thompson, will retire from the company this year. He looks back on the last eight years of progress for CGT Catapult and the advanced therapies sector – and provides words of wisdom for the challenges still to come.
The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.
In case you missed it: catch up with snippets from interviews with industry leaders recently published by In Vivo.